Sequential Vinorelbine and Docetaxel in Advanced Non-small Cell Lung Cancer Patients Age 70 and Older and/or with a Performance Status of 2: A Phase II Trial of the Southwest Oncology Group (S0027)-Reference-Cited by-同舟云学术

Sequential Vinorelbine and Docetaxel in Advanced Non-small Cell Lung Cancer Patients Age 70 and Older and/or with a Performance Status of 2: A Phase II Trial of the Southwest Oncology Group (S0027)

Published:2006-07 Issue:6 Volume:1 Page:537-544
ISSN:1556-0864
Container-title:Journal of Thoracic Oncology
language:en
Short-container-title:Journal of Thoracic Oncology

Author:

Hesketh Paul J.,Chansky Kari,Lau Derick H. M.,Doroshow James H.,Moinpour Carol M.,Chapman Robert A.,Goodwin J Wendall,Gross Howard M.,Crowley John J.,Gandara David R.

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine,Oncology

Reference48 articles.

1. Chemotherapy for advanced non-small-cell lung cancer: how much benefit is enough?

2. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials

3. Polychemotherapy in advanced non small cell lung cancer: a meta-analysis

4. Chemotherapy vs Supportive Care in Advanced Non-Small-Cell Lung Cancer

5. Underrepresentation of Patients 65 Years of Age or Older in Cancer-Treatment Trials

Cited by 24 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Association Between Health-Related Quality of Life and Progression-Free Survival in Patients With Advanced Cancer: A Secondary Analysis of SWOG Clinical Trials;JCO Oncology Practice;2021-10-04

2. Association of Fatigue and Outcomes in Advanced Cancer: An Analysis of Four SWOG Treatment Trials;JCO Oncology Practice;2021-08

3. The Complementary Nature of Patient-Reported Outcomes and Adverse Event Reporting in Cooperative Group Oncology Clinical Trials: A Pooled Analysis (NCCTG N0591);Journal of Pain and Symptom Management;2015-10

4. Erlotinib Plus Capecitabine as First-Line Treatment for Older Chinese Patients With Advanced Adenocarcinoma of the Lung (C-TONG0807);Medicine;2015-01

5. Risk Factors for Cisplatin-Induced Nephrotoxicity and Potential of Magnesium Supplementation for Renal Protection;PLoS ONE;2014-07-14